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background:  Heparin is commonly used as the sole procedural anticoagulant in patients undergoing primary PCI (PPCI). Use of Bivalirudin 
compared with platelet glycoprotein IIbIIIa inhibitors (GPI) has been associated with improved survival in this cohort. There are no data on the 
comparative effectiveness of heparin versus bivalirudin in this population.
methods:  We compared the outcome of patients undergoing PPCI and treated with Bivalirudin versus Heparin only across 47 hospitals in Michigan 
between 2010 and 2012. Propensity score matching (PSM) on a 1:1 basis without replacement and multivariate logistic and Cox proportional 
hazards regression models were utilized to account for confounding.
results:  Of 4,035 admissions for PPCI included in the analysis, Bivalirudin was used in 2,059 (51%) and heparin in 1,976 (49%). 1,622 (82%) 
heparin patients were successfully matched to bivalirudin patients using PSM. After adjusting for baseline covariates, Heparin use was associated 
with significantly greater in-hospital mortality in the overall cohort (10.6% versus 4.5%, Adjusted OR = 1.85, 95% CI 1.36 - 2.52, p < 0.001) and 
after PSM (7.3% versus 4.6%, Adjusted OR = 1.91, 95% CI 1.33 - 2.73, p <0 .001). Heparin use was independently associated with higher long-term 
mortality (median follow up of 1 year, HR = 1.48, 95% CI 1.07 - 2.01, p =.018).
Conclusions:  Heparin monotherapy in PPCI is associated with increased in-hospital and long term-mortality compared to Bivalirudin.
